<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77284">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01971645</url>
  </required_header>
  <id_info>
    <org_study_id>IRB13-00610</org_study_id>
    <nct_id>NCT01971645</nct_id>
  </id_info>
  <brief_title>Decadron as Adjuvant in Femoral Nerve Blocks in Knee Arthroscopy</brief_title>
  <official_title>Dexamethasone as an Adjuvant to Ropivacaine for Femoral Nerve Blocks in Children Undergoing Knee Arthroscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nationwide Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nationwide Children's Hospital</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      If preservative-free dexamethasone 0.1 mg/kg (max dose 4 mg) is added to ropivacaine 0.5% 2
      mg/kg (max dose 100 mg), then post-PACU opioid consumption will be reduced by 33%.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Post-PACU opioid consumption</measure>
    <time_frame>48 hours post-operatively</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Knee Arthroscopy</condition>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group D patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) with 0.1 mg/kg preservative-free dexamethasone (max. dose 4 mg) perineurally for their femoral block.  Group D will also receive a gluteal intramuscular injection of saline of volume equivalent to 0.1 mg/kg preservative-free dexamethasone (max. volume 0.4 ml).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group R</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group R patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) combined with a volume of saline equivalent to 0.1 mg/kg preservative-free dexamethasone (max. volume 0.4 ml) perineurally.  Group R will also receive a gluteal intramuscular injection of saline of volume equivalent to 0.1 mg/kg preservative-free dexamethasone (max. volume 0.4 ml).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group M</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group M patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) combined with a volume of saline equivalent to 0.1 mg/kg preservative-free dexamethasone (max. volume 0.4 ml) perineurally.  Group M will also receive a gluteal intramuscular injection of 0.1 mg/kg preservative-free dexamethasone (max. dose 4 mg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Patients may receive 0.1 mg/kg preservative-free dexamethasone (max. dose 4 mg) either perineurally or intramuscularly.</description>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_label>Group M</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>Patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) perineurally.</description>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_label>Group R</arm_group_label>
    <arm_group_label>Group M</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children older than 10, and younger than 19 years of age undergoing unilateral
             arthroscopic surgery of the knee

          -  American Society of Anesthesiologists (ASA) Status I or II

          -  Patient's parent/guardian willing and able to give consent

          -  Patient willing to give assent

        Exclusion Criteria:

          -  Arthroscopic anterior cruciate ligament repair

          -  Systemic steroid use within the last 3 months

          -  Diabetes mellitus

          -  Females testing positive for pregnancy

          -  BMI &gt; 98th percentile

          -  Positive pregnancy test

          -  Coagulopathy

          -  Renal or hepatic disease

          -  Pre-existing motor or sensory deficits in the lower extremities

          -  Predisposition for falls based on pre-existing sensory or motor deficits of the legs
             or inability to perform crutch training.

          -  Non-English speaking

          -  Systemic fungal infection

          -  Immunosuppressed patients
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giorgio Veneziano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nationwide Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>N'Diris Barry, BS, RN, BSN</last_name>
    <phone>(614) 355-3467</phone>
    <email>N'Diris.Barry@NationwideChildrens.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie Rice, RN, BSN</last_name>
    <phone>(614) 355-3142</phone>
    <email>Julie.Rice@NationwideChildrens.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giorgio Veneziano, MD</last_name>
      <phone>614-722-4200</phone>
      <email>Giorgio.Veneziano@NationwideChildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>N'Diris Barry, BS, RN, BSN</last_name>
      <phone>(614) 355-3467</phone>
      <email>N'Diris.Barry@NationwideChildrens.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 15, 2014</lastchanged_date>
  <firstreceived_date>October 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nationwide Children's Hospital</investigator_affiliation>
    <investigator_full_name>Giorgio Veneziano</investigator_full_name>
    <investigator_title>Assistant Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Dexamethasone</keyword>
  <keyword>Ropivacaine</keyword>
  <keyword>Knee arthroscopy</keyword>
  <keyword>Femoral nerve blocks</keyword>
  <keyword>Peripheral nerve blocks</keyword>
  <keyword>Adjuvant</keyword>
  <keyword>Pediatrics</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
